Author
Listed:
- Stephen J. Pettitt
(The Institute of Cancer Research
The Institute of Cancer Research)
- Dragomir B. Krastev
(The Institute of Cancer Research
The Institute of Cancer Research)
- Inger Brandsma
(The Institute of Cancer Research
The Institute of Cancer Research)
- Amy Dréan
(The Institute of Cancer Research
The Institute of Cancer Research)
- Feifei Song
(The Institute of Cancer Research
The Institute of Cancer Research)
- Radoslav Aleksandrov
(Bulgarian Academy of Sciences)
- Maria I. Harrell
(University of Washington School of Medicine)
- Malini Menon
(The Institute of Cancer Research
The Institute of Cancer Research)
- Rachel Brough
(The Institute of Cancer Research
The Institute of Cancer Research)
- James Campbell
(The Institute of Cancer Research
The Institute of Cancer Research)
- Jessica Frankum
(The Institute of Cancer Research
The Institute of Cancer Research)
- Michael Ranes
(The Institute of Cancer Research)
- Helen N. Pemberton
(The Institute of Cancer Research
The Institute of Cancer Research)
- Rumana Rafiq
(The Institute of Cancer Research
The Institute of Cancer Research)
- Kerry Fenwick
(The Institute of Cancer Research)
- Amanda Swain
(The Institute of Cancer Research)
- Sebastian Guettler
(The Institute of Cancer Research)
- Jung-Min Lee
(National Cancer Institute)
- Elizabeth M. Swisher
(University of Washington School of Medicine)
- Stoyno Stoynov
(Bulgarian Academy of Sciences)
- Kosuke Yusa
(Wellcome Trust Sanger Institute)
- Alan Ashworth
(UCSF Helen Diller Family Comprehensive Cancer Center)
- Christopher J. Lord
(The Institute of Cancer Research
The Institute of Cancer Research)
Abstract
Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 “tag-mutate-enrich” mutagenesis screens, we identify close to full-length mutant forms of PARP1 that cause in vitro and in vivo PARPi resistance. Mutations both within and outside of the PARP1 DNA-binding zinc-finger domains cause PARPi resistance and alter PARP1 trapping, as does a PARP1 mutation found in a clinical case of PARPi resistance. This reinforces the importance of trapped PARP1 as a cytotoxic DNA lesion and suggests that PARP1 intramolecular interactions might influence PARPi-mediated cytotoxicity. PARP1 mutations are also tolerated in cells with a pathogenic BRCA1 mutation where they result in distinct sensitivities to chemotherapeutic drugs compared to other mechanisms of PARPi resistance (BRCA1 reversion, 53BP1, REV7 (MAD2L2) mutation), suggesting that the underlying mechanism of PARPi resistance that emerges could influence the success of subsequent therapies.
Suggested Citation
Stephen J. Pettitt & Dragomir B. Krastev & Inger Brandsma & Amy Dréan & Feifei Song & Radoslav Aleksandrov & Maria I. Harrell & Malini Menon & Rachel Brough & James Campbell & Jessica Frankum & Michae, 2018.
"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance,"
Nature Communications, Nature, vol. 9(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03917-2
DOI: 10.1038/s41467-018-03917-2
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Frederick Richards & Marta J. Llorca-Cardenosa & Jamie Langton & Sara C. Buch-Larsen & Noor F. Shamkhi & Abhishek Bharadwaj Sharma & Michael L. Nielsen & Nicholas D. Lakin, 2023.
"Regulation of Rad52-dependent replication fork recovery through serine ADP-ribosylation of PolD3,"
Nature Communications, Nature, vol. 14(1), pages 1-14, December.
- Ke Cong & Nathan MacGilvary & Silviana Lee & Shannon G. MacLeod & Jennifer Calvo & Min Peng & Arne Nedergaard Kousholt & Tovah A. Day & Sharon B. Cantor, 2024.
"FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells,"
Nature Communications, Nature, vol. 15(1), pages 1-14, December.
- Simon D. Schwarz & Jianming Xu & Kapila Gunasekera & David Schürmann & Cathrine B. Vågbø & Elena Ferrari & Geir Slupphaug & Michael O. Hottiger & Primo Schär & Roland Steinacher, 2024.
"Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation,"
Nature Communications, Nature, vol. 15(1), pages 1-13, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03917-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.